Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Advertise in Pharma in Focus

Advertising in Pharma in Focus delivers you:

  • Unique access to a $17 billion industry
  • High visibility with over 11,500 readers every working day
  • Great reaction with click through rates of up to 6.5%
  • Unparalled contact via unique beyond-the-click services

For more information, ring 02 9938 4381

Approvals Action
Gilead's Viread replacement registered
Gilead has won registration for chronic hepatitis B treatment Vemlidy, its replacement drug for Viread in that indication, which will soon be facing generic competition.
Pipeline Monitor
Celgene scores with old and new drugs
Celgene's Revlimid has won an additional indication in the US while the company's potential blockbuster, ozanimod, has enjoyed success in a head-to- had trial against Biogen's Avonex.
Debating Point
Expert games not very convincing
Both sides in the battle over the future of biosimilar prescribing in Australia have been rolling out their foreign experts but it's hard to see how fly-in, fly-out expertise can influence a government facing multiple budget management problems at home.